Cargando…
S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428227/ http://dx.doi.org/10.1097/01.HS9.0000967764.47851.65 |
| _version_ | 1785090416403546112 |
|---|---|
| author | Ayala, Rosa Lopez, Nieves Abulafia, Adi Shacham Alwan, Maan Yannakou, Costas K. Raman, Indu Ribrag, Vincent Fong, Chun Yew Volchek, Yulia Bonifacio, Massimiliano Tucci, Alessandra Kiladjian, Jean-Jacques Rivas, Jésus Marïa Hernandez Xicoy, Blanca Al-Ali, Haifa Kathrin Ianotto, Jean-Christope Lee-Hoeflich, Si Tuen Das, Sharmilla Wu, Bin Ravindran, Palanikumar Zhao, Qian Wang, Guan Esposito, Oriana Liu, Yu Nikolova, Zariana Tehlirian, Christopher Coker, Shodeinde Lavie, David |
| author_facet | Ayala, Rosa Lopez, Nieves Abulafia, Adi Shacham Alwan, Maan Yannakou, Costas K. Raman, Indu Ribrag, Vincent Fong, Chun Yew Volchek, Yulia Bonifacio, Massimiliano Tucci, Alessandra Kiladjian, Jean-Jacques Rivas, Jésus Marïa Hernandez Xicoy, Blanca Al-Ali, Haifa Kathrin Ianotto, Jean-Christope Lee-Hoeflich, Si Tuen Das, Sharmilla Wu, Bin Ravindran, Palanikumar Zhao, Qian Wang, Guan Esposito, Oriana Liu, Yu Nikolova, Zariana Tehlirian, Christopher Coker, Shodeinde Lavie, David |
| author_sort | Ayala, Rosa |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428227 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104282272023-08-17 S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY Ayala, Rosa Lopez, Nieves Abulafia, Adi Shacham Alwan, Maan Yannakou, Costas K. Raman, Indu Ribrag, Vincent Fong, Chun Yew Volchek, Yulia Bonifacio, Massimiliano Tucci, Alessandra Kiladjian, Jean-Jacques Rivas, Jésus Marïa Hernandez Xicoy, Blanca Al-Ali, Haifa Kathrin Ianotto, Jean-Christope Lee-Hoeflich, Si Tuen Das, Sharmilla Wu, Bin Ravindran, Palanikumar Zhao, Qian Wang, Guan Esposito, Oriana Liu, Yu Nikolova, Zariana Tehlirian, Christopher Coker, Shodeinde Lavie, David Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428227/ http://dx.doi.org/10.1097/01.HS9.0000967764.47851.65 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Ayala, Rosa Lopez, Nieves Abulafia, Adi Shacham Alwan, Maan Yannakou, Costas K. Raman, Indu Ribrag, Vincent Fong, Chun Yew Volchek, Yulia Bonifacio, Massimiliano Tucci, Alessandra Kiladjian, Jean-Jacques Rivas, Jésus Marïa Hernandez Xicoy, Blanca Al-Ali, Haifa Kathrin Ianotto, Jean-Christope Lee-Hoeflich, Si Tuen Das, Sharmilla Wu, Bin Ravindran, Palanikumar Zhao, Qian Wang, Guan Esposito, Oriana Liu, Yu Nikolova, Zariana Tehlirian, Christopher Coker, Shodeinde Lavie, David S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY |
| title | S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY |
| title_full | S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY |
| title_fullStr | S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY |
| title_full_unstemmed | S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY |
| title_short | S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY |
| title_sort | s213: bms-986158, a potent bet inhibitor, as monotherapy and in combination with ruxolitinib or fedratinib in intermediate- or high-risk myelofibrosis (mf): results from a phase 1/2 study |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428227/ http://dx.doi.org/10.1097/01.HS9.0000967764.47851.65 |
| work_keys_str_mv | AT ayalarosa s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT lopeznieves s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT abulafiaadishacham s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT alwanmaan s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT yannakoucostask s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT ramanindu s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT ribragvincent s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT fongchunyew s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT volchekyulia s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT bonifaciomassimiliano s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT tuccialessandra s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT kiladjianjeanjacques s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT rivasjesusmariahernandez s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT xicoyblanca s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT alalihaifakathrin s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT ianottojeanchristope s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT leehoeflichsituen s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT dassharmilla s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT wubin s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT ravindranpalanikumar s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT zhaoqian s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT wangguan s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT espositooriana s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT liuyu s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT nikolovazariana s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT tehlirianchristopher s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT cokershodeinde s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study AT laviedavid s213bms986158apotentbetinhibitorasmonotherapyandincombinationwithruxolitiniborfedratinibinintermediateorhighriskmyelofibrosismfresultsfromaphase12study |